Please find all related articles below.
In a one day, launch conference, the European Gender Medicine Project (EUGenMed) partners met with ninety experts and key stakeholders to assess the role of gender medicine (GM) in Europe. The launch conference marked the first of a series of project meetings under the DG Research and Innovation-funded Framework Seven Programme (FP7) project to be held in 2014 and 2015 that will culminate in the development of a roadmap for the further implementation of sex and gender (S&G) in (...)
Brussels, 3 April 2014 – EPHA welcomes the majority of the measures adopted yesterday by the European Parliament as part of the revision of the EU Medical Devices Directive (MDD) and the In Vitro Diagnostic Medical Devices (IVD) Directive. After a year and a half of proposals (1) and in-depth discussions, it is time to rebuild the trust of patients around Europe.
“As the protection of patient safety is a paramount objective, the European Parliament has today taken a (...)
This position paper, supported by 23 leading Global Health NGOs from both sides of the Atlantic, calls on both public and private stakeholders to ensure that R&D investment targets for poverty-related and neglected diseases (PRNDs) are guaranteed and strongly supported across the board.
Research and innovation are critical components in the right to health for all
While everybody recognises that health is an essential precondition for development, the research and innovation (...)
EPHA is organising a joint debate about the pivotal role that patients should play in creating innovative, affordable and quality technologies and products for poverty-related and neglected diseases.
To register, please RSVP with your full name and contact details at email@example.com by March 6th.
The European Commission introduced its proposal for a revision of the data protection regulations of the EU two years ago, yet despite agreement on a compromise text by the European Parliament in October 2013, completion of a finalised General Data Protection Regulation (GDPR) has now been delayed until after the May elections.
An agreement reached on 22 January between EU Justice Commissioner, Vivian Reding, and representatives of the Greek and incoming Italian Presidency, has set the new (...)
The European Partnership for Action Against Cancer (EPAAC) was launched in 2009, after the European Commission published its Communication on Action Against Cancer: European Partnership. Although this Joint Action will end in 2013, participants are committed to continue the work apart from 2014, under a renewed mandate.
What is the EPAAC all about?
After circulatory diseases, cancer was the second most common cause of death in 2006, accounting for two out of ten deaths in women and (...)
The European Commission has recently published a Staff Working Document (SWD) exploring the potential of Personalised Medicine, reporting on recent developments in the EU legislation, as well as looking at the factors affecting the uptake of personalised medicine in healthcare systems.
Personalised Medicine is now more close to be effective to patients, which means that treatments can be designed taking into account a specific patient group and hence able to tackle the problem with the (...)
Access to Medicines
Pharmaceuticals and Medicines
Health Rights and Patients
1 October, Brussels -Scientists, public health researchers and NGOs have reacted with grave concern in light of leaked copies of the European Commission’s proposed Health Research Programme 2014-2015 (part of Horizon2020) circulating in Brussels. They have raised questions regarding the preparation of this draft, given its failure to address the major personal, social, environmental and occupational risk factors of disease in favour of narrow research parameters focusing on (...)
On 25 September the European Parliaments’ Committee for the Environment and Public Health (ENVI) approved stricter rules on medical devices in order to protect the patients.
27 September, 2013 - Stricter rules on medical devices such as a new pre-market approval system, more transparency and better traceability were voted on ENVI Committee last 25 September.
Clear rules were introduced by Members of the European Parliament (MEPs) to boost public access to clinical data, create a new (...)
The European Parliament’s ENVI Committee vote on the proposals for Regulations on Medical Devices and InVitro Medical Devices has been postponed for the second time. There are rising concerns by health stakeholders regarding the speed of the process, as ongoing delays undermine public trust in the EU’s ability to create legislation that will adequately protect patients.
On Wednesday 18 September, the ENVI committee postponed the vote on the Medical Devices Regulations for the (...)